

Healthier Together: Collaborative Networks of Patients, Clinicians and Researchers to Transform Chronic Illness Care




COLLABORATIVE CHRONIC CARE NETWORK

Peter Margolis, MD, PhD


December 4, 2014

Supported by: NIH NIDDK R01DK085719, AHRQ R01HS020024, AHRQ U18HS016957, PCORI PPRN-1306-01754, ImproveCareNow Network Care Centers, CCHMC Learning Networks Program




Learning Healthcare System


- Patients and providers work together to choose care based on best evidence
- Drive discovery as natural outgrowth of patient care
- Ensure innovation, quality, safety and value
- All in real-time



Network-Based Production




Benkler, Y. (2011). *The Penguin and the Leviathan: The triumph of cooperation over self-interest*. New York: Crown Business.



IMPROVE**CARE**NOW

Remission rate

(PGA, Centers >75% registered)



71 Care Centers
>19,500 patients
>575 physicians
>35% of all IBD patients

Components of a network-based Learning Health System*

1. Focus on outcome
2. Build community and culture of sharing (a 'commons')
3. Effective use of technology
4. Learning system sciences
 - Systems science, QI, qualitative research, health services research, biostatistics, epidemiology




*Collective creativity (Swarm Creativity; Peter Gloor)

Lead User innovation (Democratizing Innovation; Eric von Hippel)

New economic models (The Wealth of Networks; Yochai Benkler)

Actor-oriented organizational architecture (Configuring value for competitive advantage;

Effective use of technology to reduce costs of data collection



John Hutton, MD; Keith Marsolo, PhD; Charles Bailey, MD; Christopher Forrest, MD, PhD; Marshall Joffe, MD, PhD; Wallace Crandall, MD; Mike Kappleman, MD, MPH; Eileen King, PhD

Data-in-once (at clinical visit)

IST - EP4 PEDI GASTRO - RICHARD B COLLETTI

Epic

In Basket Chart Schedule Patient Lists Pre-Proc Encounters Referrals Charting Tools

Crohnsjr, Richard

Crohnsjr, Richard MRN: 0028007623 PCP: LARRABEE, JERRY G Allergies: Unknown; Not on File
13 y.o., Male DOB: 01/21/1998 Visit#: 590180 Infection: None

11/16/2011 visit with Colletti, Richard, MD for FOLLOW UP RETURN - test

Images References Print A/B Other Note Types Anti-Coag Enc

Snapshot

Chart Review

Flow Sheets

Results Review

Growth Chart

Synopsis

History

Allergies

Problem List

Medications

Immunizations

Demographics

Letters

Doc Flow Sheets

Order Entry

MAR

Visit Navigator

Charting

Chief Complaint

Vital Signs

Extended Vitals

Problem List

History

Social History

Allergies

Medications

Immun. Rpt

Hearing/Vision

SmartSets

Progress Notes

Dx and Orders

Disease Measurement

IBD Registry

Disease Mgmt

Medications

Verify Rx Benefits

Reconcile Dispens...

Disclaimer

Discharge

Pl. Instructions

LOS & Follow-up

Charge Capture

After Visit Summary

Close Encounter

IBD Registry

Background Information

Current diagnosis

Crohn's disease ulcerative colitis indeterminate colitis

Has the patient had a complete colectomy? (If correct information appears in the sidebar, it is okay to leave this response blank.) Yes No unknown

Does the patient currently have an ileostomy or colostomy? Yes No unknown

Current symptoms

Describe the IBD symptoms on the WORST day in the last 7 days:

General well-being

normal fair poor unknown

Limitations in daily activities

no limitations occasional frequent unknown

Abdominal pain

none mild moderate to severe unknown

Stool characteristics

Describe the stools on the WORST day in the last 7 days:

Total number of stools not available/assessed

Most stools were formed partially formed watery unknown

Number of liquid/watery stools per day (0 if none) not available/assessed

Did the patient report bloody stools? Yes No unknown

New enhanced automated pre-visit planning report

| | | |
|---|-------------------------------|-------------------------|
| Diagnosis: Crohn's Disease - 2/2008 | Last Visit: 7/2/2014 | Last PPD & Date: |
| Phenotype: Inflammatory, non-penetrating, non-stricturing | Wt (kg): 52.70 | Not Recorded |
| Lower: Ileocolonic | Ht (cm): 167.00 | Last CXR: |
| Upper Proximal: No | BSA: 1.564 | Not Recorded |
| Upper Distal: Yes | Date of last hospitalization: | Last Gold Test & Date: |
| Perianal Phenotype: No | Not Recorded | Indeterminate 6/26/2013 |

>> Visits: 05/01/2013 06/26/2013 07/10/2013 08/06/2013 01/15/2014 03/19/2014 05/07/2014 07/02/2014 Age of Result

| | 05/01/2013 | 06/26/2013 | 07/10/2013 | 08/06/2013 | 01/15/2014 | 03/19/2014 | 05/07/2014 | 07/02/2014 | Age of Result |
|--------------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|---------------|
| sPCDAI | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| PGA | Mild | Mild | Mild | Quiescent | Quiescent | Quiescent | Quiescent | Quiescent | |
| Nutritional Status | Satisfactory | Satisfactory | Satisfactory | Satisfactory | Satisfactory | Satisfactory | Satisfactory | Satisfactory | |
| Growth Status | At risk | At risk | At risk | Satisfactory | Satisfactory | Satisfactory | Satisfactory | Satisfactory | |
| Albumin | | 4.1 | 4.5 | 4.2 | 4.4 | 4.2 | 4.5 | 4.2 | 1 mo |
| CRP | | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1 mo |
| ESR | | 25.0 | | 11.0 | 40.5 | 8.0 | 9.0 | 3.0 | 1 mo |
| Hematocrit | | 37.5 | 38.8 | 39.4 | | 39.0 | 41.2 | 40.5 | 1 mo |

*Result date may differ from visit date

Lab ordering guidelines: 5-ASA:q6mo 6mp/ASA/MTX:q3-4mo Biologics:q2-3mo

Care Stratification

| CS Score | CSS Group | Current Disease Activity | 12 Month Disease Activity | BMI Z-Score | Ht Velocity | Hosp Adm within 3 months | Currently on Cortico | Cortico last 12 months | Psychosocial Risk Factors |
|----------|-----------|--------------------------|---------------------------|--------------------------------|---|--------------------------|----------------------|------------------------|---------------------------|
| 0 | 0-3 (Low) | 0 (Quiescent) | 0 (Quiescent) | 0 (BMI Z-score >=1 or Missing) | 0 (Ht Velocity Z-score >=1 or Missing or N/A) | 0 (No or Unknown) | 0 (No or Unknown) | 0 (No or Unknown) | No |

Automated population management report


ImproveCareNow > Data > SSRS_Data

Actions | | | | 3 of 7 | | | Find Next |


Document Map

- [-] PatientGroups
 - [-] Care Stratification Score
 - Care Stratification Score
 - Current Disease Activity - CSS
 - 12 Month Disease Activity - CSS
 - BMI Z-score - CSS
 - Height Velocity Z-score - CSS
 - IBD-Related Hospital Admission within 3 Months - CSS
 - Current Corticosteroid Use - CSS
 - Corticosteroid Use in the Last 3-12 Months - CSS
 - Psychosocial Risk Factors - CSS
 - [-] Clinical Reports
 - Diagnosis at the last visit
 - Remission Status**
 - Nutritional Status
 - Growth Status
 - TPMT Activity
 - Visit within 200 Days
 - Sustained Remission
 - [-] Demographic Reports
 - Patients by Race
 - Patients by Gender
 - Patients by Age Group
 - [-] Medication Use
 - Thiopurine is at least the dose recommended in the Model Care Guideline
 - Infliximab Dose is at least 4.5 mg/kg
 - Methotrexate Dose is at least 10 mg/m2 or 15 mg/wk
 - Prednisone Free Remission
 - Prednisone Usage

[-] Switch



[-] Switch



Data as of 12/10/2013

Reporting Month: 2013-11


Reporting Center: Vermont Children's Hospital

[Export Center Data To Excel](#)
[All Center Measures - Small Multiples Graphs](#)
[All Centers Performance Report](#)
[All Graphs Per Center Report](#)
[Dashboard With Sparkline](#)
[All Measures Per Center - Small Multiples Graphs](#)
[Gap Analysis Report](#)

| Measure Group | Sub Group | Measure Title | Network Target | >=75% cohort Teams' Performance | Team's Performance |
|---|-------------------------------|---|----------------|---------------------------------|--------------------|
| Clinical Measures | Clinical Remission | Percent of patients in remission | 80 | 77 | 80 |
| | | Percent of patients with prednisone-free remission | 76 | 74 | 75 |
| | | Percent of patients with sustained remission | 45 | 47 | 48 |
| | | Percent of patients not taking prednisone | 95 | 93 | 91 |
| | Adequate Nutrition and Growth | Percent of patients with satisfactory nutritional status | 90 | 90 | 100 |
| | | Percent of patients with at risk of nutritional failure | | 9 | 0 |
| | | Percent of patients in nutritional failure | | 2 | 0 |
| | | Percent of patients with satisfactory growth status | 90 | 92 | 98 |
| | | Percent of patients with at risk of growth failure | | 6 | 2 |
| | | Percent of patients in growth failure | | 2 | 0 |
| | Model Classification | Percent of visits with a complete bundle | 95 | 85 | 91 |
| | Model Treatment | Percent of patients with a documented visit within the last 200 days | 80 | 76 | 83 |
| | | Percent of patients whose dose of thiopurine is at least the dose recommended in the ICN Model Care Guidelines | 80 | 67 | 71 |
| | | Percent of visits where initial dose of anti-TNF therapy is given that patient had a TB test within the prior 12 months | 95 | 88 | 50 |
| | | Percent of Patients where the dose of infliximab is at least 4.5 mg/kg | 95 | 95 | 92 |
| | Data Quality | Percent of population registered AND active in registry | | 75 | 98 |
| Percent of actual visits recorded in registry | | | 83 | 100 | |
| Percent of visits with all critical data recorded | | | 88 | 91 | |
| Percent of visits meeting the consistency bundle | | | 85 | 71 | |
| Percent of visits entered that were entered within 30 days of visit date ***-*** Data reported on a two month lag | | | 98 | 100 | |
| Percent of active patients in registry with visit recorded in last 13 months | | | 92 | 98 | |

Remission rate


(PGA, Centers >75% registered)




Two Types of Research

- Research on Networks
 - What motivates people to participate and contribute and improve?
 - Who are the users of the system? What are their goals and needs?
- Research using the network for clinical research
 - What treatments work best for whom?

Social Network Analysis




Example High-Remission Hospital with Clustered QI Discussion




Example Lower-Remission Hospital with Scattered QI Discussion

Ron Burt, PhD, David Meltzer, MD, PhD,
Gavin Hougham, PhD

Social norms drive coordination and better outcomes



Social norm = people have many colleagues with whom they discuss QI AND colleagues also have many people with whom they discuss QI




Anti-TNF antibodies - 1993

**5 years later FDA approval
for Crohn's disease - 1998**

**14 years later – 1st pediatric controlled
clinical trial → REACH - 2007**

But....treatment effects estimated without a comparison group

Bianca Simmons, Age 20



“What does not kill you makes you stronger.”

Bianca's Goals

- Keep symptoms at bay
- Be a leader in the IBD community

Personalized Learning

19 yr. old with Crohn's colitis


Colectomy with ileo-anal anastomosis (10 yrs)

Chronic diarrhea, nocturnal stools, fatigue, poor quality of life

Current medications: Infliximab & PRN imodium

● Infliximab

Nocturnal (I chart)



Platform Components

Mobile App/Web App: Families/Patients

- Tracking Symptoms
- Patient Notes
- Visualize Data
- Health Reports
- Survey delivery



Desktop/Web: Providers and Families

- Population review
- Patient data review
- Note review and response
- User setup and administration
- Study administration



Cloud-Based Data Service

- Wearable device integration
- SMS / Email / Mobile integration
- EMR interoperability
- User engagement analytics
- Rapid multi-site deployment

Engagement

Being part of the distributed learning health system,

- to produce information, knowledge, and know-how
- for improving
 - personal health and
 - the health care system

Includes patients, families, clinicians and health system leaders




100%

90%

9%


1%



A contributor



No one asked anyone to make
these contributions.....



Thank you cards....

- “Thank you for believing in us and giving us the opportunity to work with ICN”
- “It was amazing to craft my own scope of work and run with it.”
- “I know I don’t need to say thanks, and I know action is needed....but I want to (say thanks). ICN has changed my life more than IBD. Isn’t that an amazing thing?”

Steal shamelessly, share seamlessly

Common Purpose
Generosity and Contribution
Mastery
Continuous Improvement
Learning
Trust
Friendship
Solidarity
Respect
Hope
Gratitude

ImproveCareNow Network is becoming a *system* for health and productivity

Personal satisfaction, engagement
and meaning

A C3N is a Distributed Learning Health System


- **Engages all stakeholders** (patients, clinicians, researchers) in advancing health of children and co-developing the system
- **Measurable impact** on health of participating children
- Reduces **time from knowledge generation to patient impact from years to months**
- **A lab** to prototype and test innovations and respond to priorities for research and outcomes data
- Generate **new evidence - faster, cheaper, and with higher quality** than conventional scientific models



Questions

- In what sequence should the components of a learning health system be created?
- What system redesigns are needed to unleash the interdependent work among patients, clinicians and researchers? In the clinic? In the research setting?
- How will the hazards of new options be recognized and prevented?
- What are the financial implications of significant co-contribution and networked research?
- How will training have to change for co-produced care and collaborative research?

Trajectory Towards Improved Remission Rates



Thanks to Ted Denson, MD



Our mission is simple....

“ to engage and empower patients/parents to have a voice for those impacted by

A Platform for Network Production

- Social process engender trust and collaboration
 - Transparency of results data
 - Processes for patients, families, clinicians, researchers to interact and contribute
 - Competency-based training
- Technology
 - Interoperable data model and data sharing for CER
 - Longitudinal PRO
 - Fully linked biorepository
 - Registry based trial recruitment
- Scientific
 - Multi-stakeholder informed research agenda
 - Multiple large CER studies
 - Registry based trials
 - Aggregated “N of 1” data
 - “Data mining”
- Policy
 - Central IRB
 - Data sharing, privacy and ethics policies
 - IP Commons

Purpose of ImproveCareNow

Transform the **health, care and costs** for **all** children and adolescents with Crohn's disease and ulcerative colitis by building a sustainable **collaborative chronic care network**, enabling patients, families, clinicians and researchers to work together in a **learning health care system** to **accelerate innovation, discovery and the application of new knowledge.**

September 2012